Biomaterial Based Stem Cells Therapy for Cancer

Akanksha      Pandey; Rishabha      Malviya; Pramod   Kumar   Sharma; Kalpana      Rahate
doi:10.2174/1574888X18666230110154333
Abstract

Biomaterials are developed to aid a variety of regenerative medicine strategies, such as providing a framework for cell adhesion and proliferation or serving as carriers of bioactive factors, while stem cells are increasingly implanted in biomaterial scaffolds to improve therapeutic efficacy. Advanced biomaterials like metals, synthetic polymers, and ceramics are used in bone regeneration technology. The ultimate goal of biomaterial-directed SC (stem cells) culture is to replicate the physical and biochemical characteristics of the physiological SC niche. The primary structural component of tumour ECM (extracellular matrix) is collagen. Cancer initiation, EMT (epithelial-mesenchymal transition), drug resistance, and CSC (cancer stem cells) self-renewal have all been linked to collagen subtypes. The enhancement of liver CSCs has already been investigated using collagen I-based platforms. Alginate and chitosan are two naturally occurring polymers with biological macromolecules that are similar. Biomaterial-based therapies, on the whole, offer incredible versatility and tailorability in the fight against the disease. They could also be used as tissue-engineered scaffolds for immune cell replenishment, potentially making them a key weapon in the next generation of therapeutic approaches.
Keywords: Stem cell therapy, biomaterial, cancer, patient care, cancer treatment, collagen.
« Previous Next »
Graphical Abstract

[1]
Qi C, Yan X, Huang C, Melerzanov A, Du Y. Biomaterials as carrier, barrier and reactor for cell-based regenerative medicine. Protein Cell  2015; 6(9): 638-53.
 [http://dx.doi.org/10.1007/s13238-015-0179-8] [PMID:  26088192]

[2]
Discher DE, Janmey P, Wang Y. Tissue cells feel and respond to the stiffness of their substrate. Science  2005; 310(5751): 1139-43.
 [http://dx.doi.org/10.1126/science.1116995] [PMID:  16293750]

[3]
Peng H, Liu X, Wang G, et al. Polymeric multifunctional nanomaterials for theranostics. J Mater Chem B Mater Biol Med  2015; 3(34): 6856-70.
 [http://dx.doi.org/10.1039/C5TB00617A] [PMID:  32262535]

[4]
Mao AS, Mooney DJ. Regenerative medicine: Current therapies and future directions. Proc Natl Acad Sci USA  2015; 112(47): 14452-9.
 [http://dx.doi.org/10.1073/pnas.1508520112] [PMID:  26598661]

[5]
Jayaraman P, Gandhimathi C, Venugopal JR, Becker DL, Ramakrishna S, Srinivasan DK. Controlled release of drugs in electrosprayed nanoparticles for bone tissue engineering. Adv Drug Deliv Rev  2015; 94: 77-95.
 [http://dx.doi.org/10.1016/j.addr.2015.09.007] [PMID:  26415888]

[6]
Cao W, Liu J, Wang L, et al. Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors. Carcinogenesis  2019; 40(1): 145-54.
 [http://dx.doi.org/10.1093/carcin/bgy129] [PMID:  30289434]

[7]
Zhang S, Liu Y, Zhang X, et al. Prostaglandin E 2 hydrogel improves cutaneous wound healing via M2 macrophages polarization. Theranostics  2018; 8(19): 5348-61.
 [http://dx.doi.org/10.7150/thno.27385] [PMID:  30555551]

[8]
Lam MT, Wu JC. Biomaterial applications in cardiovascular tissue repair and regeneration. Expert Rev Cardiovasc Ther  2012; 10(8): 1039-49.
 [http://dx.doi.org/10.1586/erc.12.99] [PMID:  23030293]

[9]
Lau EYT, Ho NPY, Lee TKW. Cancer stem cells and their microenvironment: biology and therapeutic implications. Stem Cells Int  2017; 2017(17): 1-11.
 [http://dx.doi.org/10.1155/2017/3714190] [PMID:  28337221]

[10]
Ottenbrite RM, Kim SW. Polymeric drugs and drug delivery systems. Florida, USA: CRC Press 2019.
 [http://dx.doi.org/10.1201/9780429136405]

[11]
Kleinsmith LJ, Pierce GB Jr. Multipotentiality of single embryonal carcinoma cells. Cancer Res  1964; 24: 1544-51.
 [PMID:  14234000]

[12]
Schätzlein AG. Delivering cancer stem cell therapies – A role for nanomedicines? Eur J Cancer  2006; 42(9): 1309-15.
 [http://dx.doi.org/10.1016/j.ejca.2006.01.044] [PMID:  16682183]

[13]
Greaves M, Maley CC. Clonal evolution in cancer. Nature  2012; 481(7381): 306-13.
 [http://dx.doi.org/10.1038/nature10762] [PMID:  22258609]

[14]
Farrar WL. Cancer stem cells. N Engl J Med  2005; 355: 1-191.

[15]
Marotta LLC, Polyak K. Cancer stem cells: A model in the making. Curr Opin Genet Dev  2009; 19(1): 44-50.
 [http://dx.doi.org/10.1016/j.gde.2008.12.003] [PMID:  19167210]

[16]
Clevers H. The cancer stem cell: Premises, promises and challenges. Nat Med  2011; 17(3): 313-9.
 [http://dx.doi.org/10.1038/nm.2304] [PMID:  21386835]

[17]
Wicha MS, Liu S, Dontu G. Cancer stem cells: An old idea--a paradigm shift. Cancer Res  2006; 66(4): 1883-90.
 [http://dx.doi.org/10.1158/0008-5472.CAN-05-3153] [PMID:  16488983]

[18]
Kaiser J. The cancer stem cell gamble. Science  2015; 347(6219): 226-9.
 [http://dx.doi.org/10.1126/science.347.6219.226] [PMID:  25593170]

[19]
Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol  2007; 17(2): 165-72.
 [http://dx.doi.org/10.1016/j.cub.2006.11.033] [PMID:  17196391]

[20]
Chew SA, Danti S. Biomaterial‐based implantable devices for cancer therapy. Adv Healthc Mater  2017; 6(2): 1600766.
 [http://dx.doi.org/10.1002/adhm.201600766] [PMID:  27886461]

[21]
Fong ELS, Lamhamedi-Cherradi SE, Burdett E, et al. Modeling Ewing sarcoma tumors in vitro with 3D scaffolds. Proc Natl Acad Sci USA  2013; 110(16): 6500-5.
 [http://dx.doi.org/10.1073/pnas.1221403110] [PMID:  23576741]

[22]
Bersini S, Jeon JS, Dubini G, et al. A microfluidic 3D in vitro model for specificity of breast cancer metastasis to bone. Biomaterials  2014; 35(8): 2454-61.
 [http://dx.doi.org/10.1016/j.biomaterials.2013.11.050] [PMID:  24388382]

[23]
Chikkaveeraiah BV, Bhirde A, Malhotra R, Patel V, Gutkind JS, Rusling JF. Single-wall carbon nanotube forest arrays for immunoelectrochemical measurement of four protein biomarkers for prostate cancer. Anal Chem  2009; 81(21): 9129-34.
 [http://dx.doi.org/10.1021/ac9018022] [PMID:  19775154]

[24]
Mani V, Chikkaveeraiah BV, Patel V, Gutkind JS, Rusling JF. Ultrasensitive immunosensor for cancer biomarker proteins using gold nanoparticle film electrodes and multienzyme-particle amplification. ACS Nano  2009; 3(3): 585-94.
 [http://dx.doi.org/10.1021/nn800863w] [PMID:  19216571]

[25]
Kim KS, Park W, Hu J, Bae YH, Na K. A cancer-recognizable MRI contrast agents using pH-responsive polymeric micelle. Biomaterials  2014; 35(1): 337-43.
 [http://dx.doi.org/10.1016/j.biomaterials.2013.10.004] [PMID:  24139764]

[26]
Ewend MG, Sampath P, Williams JA, Tyler BM, Brem H. Local delivery of chemotherapy prolongs survival in experimental brain metastases from breast carcinoma. Neurosurgery  1998; 43(5): 1185-92.
 [http://dx.doi.org/10.1097/00006123-199811000-00093] [PMID:  9802862]

[27]
Frazier JL, Wang PP, Case D, et al. Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma. J Neurooncol  2003; 64(3): 203-9.
 [http://dx.doi.org/10.1023/A:1025695423097] [PMID:  14558595]

[28]
Minelli C, Lowe SB, Stevens MM. Engineering nanocomposite materials for cancer therapy. Small  2010; 6(21): 2336-57.
 [http://dx.doi.org/10.1002/smll.201000523] [PMID:  20878632]

[29]
Frank A, Eric M, Robert L, Omid C. Nanoparticle technologies for cancer therapy. In: Handbook of Experimental Pharmacology.  Springer 2010; 197: pp. 55-86.

[30]
Nsereko S, Amiji M. Localized delivery of paclitaxel in solid tumors from biodegradable chitin microparticle formulations. Biomaterials  2002; 23(13): 2723-31.
 [http://dx.doi.org/10.1016/S0142-9612(02)00005-4] [PMID:  12059022]

[31]
Peng Z, Wang C, Fang E, Lu X, Wang G, Tong Q. Co-delivery of doxorubicin and SATB1 shRNA by thermosensitive magnetic cationic liposomes for gastric cancer therapy. PLoS One  2014; 9(3): e92924.
 [http://dx.doi.org/10.1371/journal.pone.0092924] [PMID:  24675979]

[32]
Kaminskas LM, McLeod VM, Ryan GM, et al. Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. J Control Release  2014; 183: 18-26.
 [http://dx.doi.org/10.1016/j.jconrel.2014.03.012] [PMID:  24637466]

[33]
Liu Z, Fan AC, Rakhra K, et al. Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. Angew Chem Int Ed  2009; 48(41): 7668-72.
 [http://dx.doi.org/10.1002/anie.200902612] [PMID:  19760685]

[34]
Ong ZY, Wiradharma N, Yang YY. Strategies employed in the design and optimization of synthetic antimicrobial peptide amphiphiles with enhanced therapeutic potentials. Adv Drug Deliv Rev  2014; 78: 28-45.
 [http://dx.doi.org/10.1016/j.addr.2014.10.013] [PMID:  25453271]

[35]
Ku SH, Kim K, Choi K, Kim SH, Kwon IC. Tumor-targeting multifunctional nanoparticles for siRNA delivery: Recent advances in cancer therapy. Adv Healthc Mater  2014; 3(8): 1182-93.
 [http://dx.doi.org/10.1002/adhm.201300607] [PMID:  24577795]

[36]
Steichen SD, Caldorera-Moore M, Peppas NA. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci  2013; 48(3): 416-27.
 [http://dx.doi.org/10.1016/j.ejps.2012.12.006] [PMID:  23262059]

[37]
Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat Rev Drug Discov  2008; 7(9): 771-82.
 [http://dx.doi.org/10.1038/nrd2614] [PMID:  18758474]

[38]
Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature  1994; 367(6464): 645-8.
 [http://dx.doi.org/10.1038/367645a0] [PMID:  7509044]

[39]
Saini M, Roser F, Hussein S, Samii M, Bellinzona M. Intralesional mitoxantrone biopolymer-mediated chemotherapy prolongs survival in rats with experimental brain tumors. J Neurooncol  2004; 68(3): 225-32.
 [http://dx.doi.org/10.1023/B:NEON.0000033381.96370.6b] [PMID:  15332325]

[40]
Wahlberg LU, Almqvist PM, Glantz MJ, Boëthius J. Polymeric controlled-release amsacrine chemotherapy in an experimental glioma model. Acta Neurochir (Wien)  1996; 138(11): 1323-9.
 [http://dx.doi.org/10.1007/BF01411063] [PMID:  8980737]

[41]
Weingart JD, Sipos EP, Brem H. The role of minocycline in the treatment of intracranial 9L glioma. J Neurosurg  1995; 82(4): 635-40.
 [http://dx.doi.org/10.3171/jns.1995.82.4.0635] [PMID:  7897527]

[42]
Bow H, Hwang LS, Schildhaus N, et al. Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma. J Neurosurg  2014; 120(3): 662-9.
 [http://dx.doi.org/10.3171/2013.11.JNS13556] [PMID:  24359008]

[43]
Pradilla G, Legnani FG, Petrangolini G, et al. Local delivery of a synthetic endostatin fragment for the treatment of experimental gliomas. Neurosurgery  2005; 57(5): 1032-40.
 [http://dx.doi.org/10.1227/01.NEU.0000180059.33665.c1] [PMID:  16284573]

[44]
Judy KD, Olivi A, Buahin KG, et al. Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas. J Neurosurg  1995; 82(3): 481-6.
 [http://dx.doi.org/10.3171/jns.1995.82.3.0481] [PMID:  7861228]

[45]
Ikegaki N, Shimada H, Fox AM, et al. Transient treatment with epigenetic modifiers yields stable neuroblastoma stem cells resembling aggressive large-cell neuroblastomas. Proc Natl Acad Sci USA  2013; 110(15): 6097-102.
 [http://dx.doi.org/10.1073/pnas.1118262110] [PMID:  23479628]

[46]
Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell  2007; 1(5): 555-67.
 [http://dx.doi.org/10.1016/j.stem.2007.08.014] [PMID:  18371393]

[47]
Manome Y, Kobayashi T, Mori M, et al. Local delivery of doxorubicin for malignant glioma by a biodegradable PLGA polymer sheet. Anticancer Res  2006; 26(5A): 3317-26.
 [PMID:  17094447]

[48]
Jackson JK, Min W, Cruz TF, et al. A polymer-based drug delivery system for the antineoplastic agent bis(maltolato)oxovanadium in mice. Br J Cancer  1997; 75(7): 1014-20.
 [http://dx.doi.org/10.1038/bjc.1997.174] [PMID:  9083337]

[49]
Zhang X, Jackson JK, Wong W, et al. Development of biodegradable polymeric paste formulations for taxol: An in vitro and in vivo study. Int J Pharm  1996; 137(2): 199-208.
 [http://dx.doi.org/10.1016/0378-5173(96)04521-8]

[50]
Dordunoo SK, Oktaba AMC, Hunter W, Min W, Cruz T, Burt HM. Release of taxol from poly(ϵ-caprolactone) pastes: Effect of water-soluble additives. J Control Release  1997; 44(1): 87-94.
 [http://dx.doi.org/10.1016/S0168-3659(96)01510-6]

[51]
Nie Y, Zhang S, Liu N, Li Z. Extracellular matrix enhances therapeutic effects of stem cells in regenerative medicine. In: Travascio F, Ed. Composition and Function of the Extracellular Matrix in the Human Body.   2016; pp. 323-40.
 [http://dx.doi.org/10.5772/62229]

[52]
Nie Y, Li Z. Controlled nitric oxide release for tissue repair and regeneration. Turk J Biol  2016; 40(2): 316-26.
 [http://dx.doi.org/10.3906/biy-1507-143]

[53]
Feng G, Cui J, Zheng Y, Han Z, Xu Y, Li Z. Identification, characterization and biological significance of very small embryonic-like stem cells (VSELs) in regenerative medicine. Histol Histopathol  2012; 27(7): 827-33.
 [PMID:  22648539]

[54]
Mimeault M, Batra SK. Concise review: recent advances on the significance of stem cells in tissue regeneration and cancer therapies. Stem Cells  2006; 24(11): 2319-45.
 [http://dx.doi.org/10.1634/stemcells.2006-0066] [PMID:  16794264]

[55]
Evans ND, Gentleman E, Polak JM. Scaffolds for stem cells. Mater Today  2006; 9(12): 26-33.
 [http://dx.doi.org/10.1016/S1369-7021(06)71740-0]

[56]
Mitjavila-Garcia MT, Simonin C, Peschanski M. Embryonic stem cells: meeting the needs for cell therapy. Adv Drug Deliv Rev  2005; 57(13): 1935-43.
 [PMID:  16257083]

[57]
Syed BA, Evans JB. Stem cell therapy market. Nat Rev Drug Discov  2013; 12(3): 185-6.
 [http://dx.doi.org/10.1038/nrd3953] [PMID:  23449299]

[58]
Han J, Menicanin D, Gronthos S, Bartold PM. Stem cells, tissue engineering and periodontal regeneration. Aust Dent J  2014; 59 (Suppl. 1): 117-30.
 [http://dx.doi.org/10.1111/adj.12100] [PMID:  24111843]

[59]
Nie Y, Zhang K, Zhang S, et al. Nitric oxide releasing hydrogel promotes endothelial differentiation of mouse. Acta Biomater  2017; 63: 190-9.
 [http://dx.doi.org/10.1016/j.actbio.2017.08.037] [PMID:  28859902]

[60]
Nallanthighal S, Heiserman JP, Cheon DJ. The role of the extracellular matrix in cancer stemness. Front Cell Dev Biol  2019; 7: 86.
 [http://dx.doi.org/10.3389/fcell.2019.00086] [PMID:  31334229]

[61]
Ganjibakhsh M, Mehraein F, Koruji M, Aflatoonian R, Farzaneh P. Three-dimensional decellularized amnion membrane scaffold as a novel tool for cancer research; cell behavior, drug resistance and cancer stem cell content. Mater Sci Eng C  2019; 100: 330-40.
 [http://dx.doi.org/10.1016/j.msec.2019.02.090] [PMID:  30948069]

[62]
Xue G, Ren Z, Grabham PW, et al. Reprogramming mediated radio-resistance of 3D-grown cancer cells. J Radiat Res (Tokyo)  2015; 56(4): 656-62.
 [http://dx.doi.org/10.1093/jrr/rrv018] [PMID:  25883172]

[63]
Chanmee T, Ontong P, Itano N. Hyaluronan: A modulator of the tumor microenvironment. Cancer Lett  2016; 375(1): 20-30.
 [http://dx.doi.org/10.1016/j.canlet.2016.02.031] [PMID:  26921785]

[64]
Florczyk SJ, Wang K, Jana S, et al. Porous chitosan-hyaluronic acid scaffolds as a mimic of glioblastoma microenvironment ECM. Biomaterials  2013; 34(38): 10143-50.
 [http://dx.doi.org/10.1016/j.biomaterials.2013.09.034] [PMID:  24075410]

[65]
Wang X, Dai X, Zhang X, Li X, Xu T, Lan Q. Enrichment of glioma stem cell-like cells on 3D porous scaffolds composed of different extracellular matrix. Biochem Biophys Res Commun  2018; 498(4): 1052-7.
 [http://dx.doi.org/10.1016/j.bbrc.2018.03.114] [PMID:  29551682]

[66]
Qiao S, Zhao Y, Li C, et al. An alginate-based platform for cancer stem cell research. Acta Biomater  2016; 37: 83-92.
 [http://dx.doi.org/10.1016/j.actbio.2016.04.032] [PMID:  27109764]

[67]
Liang Y, Jeong J, DeVolder RJ, et al. A cell-instructive hydrogel to regulate malignancy of 3D tumor spheroids with matrix rigidity. Biomaterials  2011; 32(35): 9308-15.
 [http://dx.doi.org/10.1016/j.biomaterials.2011.08.045] [PMID:  21911252]

[68]
Abbasian M, Mousavi E, Khalili M, Arab-Bafrani Z. Using of keratin substrate for enrichment of HT29 colorectal cancer stem‐like cells. J Biomed Mater Res B Appl Biomater  2019; 107(4): 1264-71.
 [http://dx.doi.org/10.1002/jbm.b.34219] [PMID:  30281900]

[69]
Chen L, Xiao Z, Meng Y, et al. The enhancement of cancer stem cell properties of MCF-7 cells in 3D collagen scaffolds for modeling of cancer and anti-cancer drugs. Biomaterials  2012; 33(5): 1437-44.
 [http://dx.doi.org/10.1016/j.biomaterials.2011.10.056] [PMID:  22078807]

[70]
Choi M, Yu SJ, Choi Y, et al. Polymer thin film–induced tumor spheroids acquire cancer stem cell–like properties. Cancer Res  2018; 78(24): 6890-902.
 [http://dx.doi.org/10.1158/0008-5472.CAN-18-0927] [PMID:  30352813]

[71]
Florczyk SJ, Kievit FM, Wang K, Erickson AE, Ellenbogen RG, Zhang M. 3D porous chitosan–alginate scaffolds promote proliferation and enrichment of cancer stem-like cells. J Mater Chem B Mater Biol Med  2016; 4(38): 6326-34.
 [http://dx.doi.org/10.1039/C6TB01713D] [PMID:  28133535]

[72]
Kievit FM, Florczyk SJ, Leung MC, et al. Proliferation and enrichment of CD133+ glioblastoma cancer stem cells on 3D chitosan-alginate scaffolds. Biomaterials  2014; 35(33): 9137-43.
 [http://dx.doi.org/10.1016/j.biomaterials.2014.07.037] [PMID:  25109438]

[73]
Liu J, Tan Y, Zhang H, et al. Soft fibrin gels promote selection and growth of tumorigenic cells. Nat Mater  2012; 11(8): 734-41.
 [http://dx.doi.org/10.1038/nmat3361] [PMID:  22751180]

[74]
Narkhede AA, Shevde LA, Rao SS. Biomimetic strategies to recapitulate organ specific microenvironments for studying breast cancer metastasis. Int J Cancer  2017; 141(6): 1091-109.
 [http://dx.doi.org/10.1002/ijc.30748] [PMID:  28439901]

[75]
Rao W, Zhao S, Yu J, Lu X, Zynger DL, He X. Enhanced enrichment of prostate cancer stem-like cells with miniaturized 3D culture in liquid core-hydrogel shell microcapsules. Biomaterials  2014; 35(27): 7762-73.
 [http://dx.doi.org/10.1016/j.biomaterials.2014.06.011] [PMID:  24952981]

[76]
Xu X, Liu C, Liu Y, et al. Enrichment of cancer stem cell-like cells by culture in alginate gel beads. J Biotechnol  2014; 177: 1-12.
 [http://dx.doi.org/10.1016/j.jbiotec.2014.02.016] [PMID:  24607645]

[77]
Liu C, Liu Y, Xu X, et al. Potential effect of matrix stiffness on the enrichment of tumor initiating cells under three-dimensional culture conditions. Exp Cell Res  2015; 330(1): 123-34.
 [http://dx.doi.org/10.1016/j.yexcr.2014.07.036] [PMID:  25108138]

[78]
Sakai S, Inamoto K, Ashida T, Takamura R, Taya M. Cancer stem cell marker-expressing cell-rich spheroid fabrication from PANC-1 cells using alginate microcapsules with spherical cavities templated by gelatin microparticles. Biotechnol Prog  2015; 31(4): 1071-6.
 [http://dx.doi.org/10.1002/btpr.2111] [PMID:  26013961]

[79]
Wang X, Dai X, Zhang X, et al. 3D bioprinted glioma cell-laden scaffolds enriching glioma stem cells via epithelial-mesenchymal transition. J Biomed Mater Res A  2019; 107(2): 383-91.
 [http://dx.doi.org/10.1002/jbm.a.36549] [PMID:  30350390]

[80]
Palomeras S, Rabionet M, Ferrer I, et al. Breast cancer stem cell culture and enrichment using poly (ε-caprolactone) scaffolds. Molecules  2016; 21(4): 537.
 [http://dx.doi.org/10.3390/molecules21040537] [PMID:  27120585]

[81]
Sawyer AJ, Piepmeier JM, Saltzman WM. New methods for direct delivery of chemotherapy for treating brain tumors. Yale J Biol Med  2006; 79(3-4): 141-52.
 [PMID:  17940624]

[82]
Lorger M. Tumor microenvironment in the brain. Cancers (Basel)  2012; 4(1): 218-43.
 [http://dx.doi.org/10.3390/cancers4010218] [PMID:  24213237]

[83]
Dolecek TA, Propp JM, Stroup NE, Kruchko C. Propp. J.M.; Stroup, N.E.; Kruchko, C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro-oncol  2012; 14 (Suppl. 5): v1-v49.
 [http://dx.doi.org/10.1093/neuonc/nos218]

[84]
Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol  2007; 114(2): 97-109.
 [http://dx.doi.org/10.1007/s00401-007-0243-4] [PMID:  17618441]

[85]
Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro‐oncology: the avenue to a cure for malignant glioma. CA: A Cancer. J for Clini  2010; 60(3): 166-93.

[86]
Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol  2003; 5(2): 79-88.
 [http://dx.doi.org/10.1093/neuonc/5.2.79] [PMID:  12672279]

[87]
Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology  1980; 30(9): 907-11.
 [http://dx.doi.org/10.1212/WNL.30.9.907] [PMID:  6252514]

[88]
Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint radiation therapy oncology group and eastern cooperative oncology group study. Cancer  1983; 52(6): 997-1007.
 [http://dx.doi.org/10.1002/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO;2-2] [PMID:  6349785]

[89]
Bodell WJ, Bodell AP, Giannini DD. Levels and distribution of BCNU in GBM tumors following intratumoral injection of DTI-015 (BCNU-ethanol). Neuro-oncol  2007; 9(1): 12-9.
 [http://dx.doi.org/10.1215/15228517-2006-014] [PMID:  17018699]

[90]
Hamstra DAI, Moffat BA, Hall DE, et al. Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor – a pharmacokinetic study. J Neurooncol  2005; 73(3): 225-38.
 [http://dx.doi.org/10.1007/s11060-004-5675-2] [PMID:  15980973]

[91]
Yimam MA, Bui T, Ho RJY. Effects of lipid association on lomustine (CCNU) administered intracerebrally to syngeneic 36B-10 rat brain tumors. Cancer Lett  2006; 244(2): 211-9.
 [http://dx.doi.org/10.1016/j.canlet.2005.12.024] [PMID:  16455196]

[92]
Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central nervous system: A review. J Pharm Pharm Sci  2003; 6(2): 252-73.
 [PMID:  12935438]

[93]
Gilhus NE, Barnes M, Brainin M. European Handbook of Neurological Management.  NJ, USA: Blackwell Publishing Ltd. 2011; Vol. 1.

[94]
Langley RR, Fidler IJ. The seed and soil hypothesis revisited-The role of tumor-stroma interactions in metastasis to different organs. Int J Cancer  2011; 128(11): 2527-35.
 [http://dx.doi.org/10.1002/ijc.26031] [PMID:  21365651]

[95]
Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys  2008; 70(2): 510-4.
 [http://dx.doi.org/10.1016/j.ijrobp.2007.06.074] [PMID:  17931798]

[96]
Tosoni A, Ermani M, Brandes AA. The pathogenesis and treatment of brain metastases: A comprehensive review. Crit Rev Oncol Hematol  2004; 52(3): 199-215.
 [http://dx.doi.org/10.1016/j.critrevonc.2004.08.006] [PMID:  15582786]

[97]
Al-Shamy G, Sawaya R. Management of brain metastases: The indispensable role of surgery. J Neurooncol  2009; 92(3): 275-82.
 [http://dx.doi.org/10.1007/s11060-009-9839-y] [PMID:  19357955]

[98]
Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J Neurooncol  2005; 75(1): 5-14.
 [http://dx.doi.org/10.1007/s11060-004-8093-6] [PMID:  16215811]

[99]
Gerrard GE, Franks KN. Overview of the diagnosis and management of brain, spine, and meningeal metastases. J Neurol Neurosurg Psychiatry  2004; 75 (Suppl. 2): ii37-42.
 [http://dx.doi.org/10.1136/jnnp.2004.040493] [PMID:  15146038]

[100]
Nguyen T, Deangelis LM. Treatment of brain metastases. J Support Oncol  2004; 2(5): 405-10.
 [PMID:  15524068]

[101]
Posner JB. Brain metastases: 1995. A brief review. J Neurooncol  1996; 27(3): 287-93.
 [http://dx.doi.org/10.1007/BF00165486] [PMID:  8847563]

[102]
Sawaya R, Ligon BL, Bindal AK, Bindal RK, Hess KR. Surgical treatment of metastatic brain tumors. J Neurooncol  1996; 27(3): 269-77.
 [http://dx.doi.org/10.1007/BF00165484] [PMID:  8847561]

[103]
Ewend MG, Brem S, Gilbert M, et al. Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. Clin Cancer Res  2007; 13(12): 3637-41.
 [http://dx.doi.org/10.1158/1078-0432.CCR-06-2095] [PMID:  17575228]

[104]
Keskar V, Mohanty PS, Gemeinhart EJ, Gemeinhart RA. Cervical cancer treatment with a locally insertable controlled release delivery system. J Control Release  2006; 115(3): 280-8.
 [http://dx.doi.org/10.1016/j.jconrel.2006.08.014] [PMID:  17034891]

[105]
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin  2005; 55(2): 74-108.
 [http://dx.doi.org/10.3322/canjclin.55.2.74] [PMID:  15761078]

[106]
Wolinsky JB, Liu R, Walpole J, Chirieac LR, Colson YL, Grinstaff MW. Prevention of in vivo lung tumor growth by prolonged local delivery of hydroxycamptothecin using poly(ester-carbonate)-collagen composites. J Control Release  2010; 144(3): 280-7.
 [http://dx.doi.org/10.1016/j.jconrel.2010.02.022] [PMID:  20184934]

[107]
Liu R, Wolinsky JB, Walpole J, et al. Prevention of local tumor recurrence following surgery using low-dose chemotherapeutic polymer films. Ann Surg Oncol  2010; 17(4): 1203-13.
 [http://dx.doi.org/10.1245/s10434-009-0856-z] [PMID:  19957041]

[108]
Langer R, Peppas N. Present and future applications of biomaterials in controlled drug delivery systems. Biomaterials  1981; 2(4): 201-14.
 [http://dx.doi.org/10.1016/0142-9612(81)90059-4] [PMID:  7034798]

[109]
Langer R, Brem H, Tapper D. Biocompatibility of polymeric delivery systems for macromolecules. J Biomed Mater Res  1981; 15(2): 267-77.
 [http://dx.doi.org/10.1002/jbm.820150212] [PMID:  7348718]

[110]
Yang MB, Tamargo RJ, Brem H. Controlled delivery of 1,3-bis(2-chloroethyl)-1-nitrosourea from ethylene-vinyl acetate copolymer. Cancer Res  1989; 49(18): 5103-7.
 [PMID:  2766281]

[111]
Loo TL, Dion RL, Dixon RL, Rall DP. The Antitumor Agent, 1,3-bis(2-chloroethyl)-1-nitrosourea. J Pharm Sci  1966; 55(5): 492-7.
 [http://dx.doi.org/10.1002/jps.2600550509]

[112]
Esther Gil-Alegre M, González-Álvarez I, Gutiérrez-Paúls L, Torres-Suárez AI. Three weeks release BCNU loaded hydrophilic-PLGA microspheres for interstitial chemotherapy: Development and activity against human glioblastoma cells. J Microencapsul  2008; 25(8): 561-8.
 [http://dx.doi.org/10.1080/02652040802075799] [PMID:  18608792]

[113]
Ren T, Ren J, Jia X, Pan K. The bone formation in vitro and mandibular defect repair using PLGA porous scaffolds. J Biomed Mater Res A  2005; 74A(4): 562-9.
 [http://dx.doi.org/10.1002/jbm.a.30324] [PMID:  16025492]

[114]
Karp JM, Shoichet MS, Davies JE. Bone formation on two-dimensional poly(DL-lactide-co-glycolide) (PLGA) films and three-dimensional PLGA tissue engineering scaffolds in vitro. J Biomed Mater Res  2003; 64A(2): 388-96.
 [http://dx.doi.org/10.1002/jbm.a.10420] [PMID:  12522827]

[115]
Wu Y, Shaw S, Lin H, Lee T, Yang C. Bone tissue engineering evaluation based on rat calvaria stromal cells cultured on modified PLGA scaffolds. Biomaterials  2006; 27(6): 896-904.
 [http://dx.doi.org/10.1016/j.biomaterials.2005.07.002] [PMID:  16125224]

[116]
Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev  1997; 28(1): 5-24.
 [http://dx.doi.org/10.1016/S0169-409X(97)00048-3] [PMID:  10837562]

[117]
Hedberg EL, Shih CK, Lemoine JJ, et al. In vitro degradation of porous poly(propylene fumarate)/poly(DL-lactic-co-glycolic acid) composite scaffolds. Biomaterials  2005; 26(16): 3215-25.
 [http://dx.doi.org/10.1016/j.biomaterials.2004.09.012] [PMID:  15603816]

[118]
Jones D, Corris S, McDonald S, Clegg JC, Farrar GH. Poly(?-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine  1997; 15(8): 814-7.
 [http://dx.doi.org/10.1016/S0264-410X(96)00266-6] [PMID:  9234522]

[119]
Kasper FK, Mikos AG. Biomaterials and gene therapy. Adv Chem Eng  2004; 29: 131-68.
 [http://dx.doi.org/10.1016/S0065-2377(03)29005-0]

[120]
Akbari H, D’Emanuele A, Attwood D. Effect of geometry on the erosion characteristics of polyanhydride matrices. Int J Pharm  1998; 160(1): 83-9.
 [http://dx.doi.org/10.1016/S0378-5173(97)00298-6]

[121]
Dang W, Daviau T, Ying P, et al. Effects of GLIADEL® wafer initial molecular weight on the erosion of wafer and release of BCNU. J Control Release  1996; 42(1): 83-92.
 [http://dx.doi.org/10.1016/0168-3659(96)01371-5]

[122]
Domb AJ, Israel ZH, Elmalak O, Teomim D, Bentolila A. Preparation and characterization of carmustine loaded polyanhydride wafers for treating brain tumors. Pharm Res  1999; 16(5): 762-5.
 [http://dx.doi.org/10.1023/A:1011995728760] [PMID:  10350022]

[123]
Sipos EP, Tyler B, Piantadosi S, Burger PC, Brem H. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother Pharmacol  1997; 39(5): 383-9.
 [http://dx.doi.org/10.1007/s002800050588] [PMID:  9054951]

[124]
Seong H, An TK, Khang G, Choi SU, Lee CO, Lee HB. BCNU-loaded poly(d, l-lactide-co-glycolide) wafer and antitumor activity against XF-498 human CNS tumor cells in vitro. Int J Pharm  2003; 251(1-2): 1-12.
 [http://dx.doi.org/10.1016/S0378-5173(02)00543-4] [PMID:  12527170]

[125]
Chae GS, Lee JS, Kim SH, et al. Enhancement of the stability of BCNU using self-emulsifying drug delivery systems (SEDDS) and in vitro antitumor activity of self-emulsified BCNU-loaded PLGA wafer. Int J Pharm  2005; 301(1-2): 6-14.
 [http://dx.doi.org/10.1016/j.ijpharm.2005.03.034] [PMID:  16024190]

[126]
Mairs RJ, Wideman CL, Angerson WJ, et al. Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model. Br J Cancer  2000; 82(1): 74-80.
 [http://dx.doi.org/10.1054/bjoc.1999.0879] [PMID:  10638969]

[127]
Wolinsky JB, Ray WC, Colson YL, Grinstaff MW. Poly (carbonate ester) s based on units of 6-hydroxyhexanoic acid and glycerol. Macromolecules  2007; 40(20): 7065-8.
 [http://dx.doi.org/10.1021/ma071276v]

[128]
Liu R, Wolinsky JB, Catalano PJ, et al. Paclitaxel-eluting polymer film reduces locoregional recurrence and improves survival in a recurrent sarcoma model: a novel investigational therapy. Ann Surg Oncol  2012; 19(1): 199-206.
 [http://dx.doi.org/10.1245/s10434-011-1871-4] [PMID:  21769471]

[129]
DeVita VT, Hellman S, Rosenberg SA. In: Biologic therapy of cancer.  (2nd ed.). Philadelphia, PA: Lippincott Williams & Wilkins 1991; pp. 743-53.

[130]
Pinto AC, Moreira JN, Simões S. Combination chemotherapy in cancer: principles, evaluation and drug delivery strategies. In: Ozdemir O, Ed. Current cancer treatment-novel beyond conventional approaches. London: IntechOpen 2011.

[131]
Cartier R, Reszka R. Utilization of synthetic peptides containing nuclear localization signals for nonviral gene transfer systems. Gene Ther  2002; 9(3): 157-67.
 [http://dx.doi.org/10.1038/sj.gt.3301635] [PMID:  11859418]

[132]
Hosseinkhani H, Azzam T, Kobayashi H, et al. Combination of 3D tissue engineered scaffold and non-viral gene carrier enhance in vitro DNA expression of mesenchymal stem cells. Biomaterials  2006; 27(23): 4269-78.
 [http://dx.doi.org/10.1016/j.biomaterials.2006.02.033] [PMID:  16620957]

[133]
Niyibizi C, Baltzer A, Lattermann C, et al. Potential role for gene therapy in the enhancement of fracture healing. Clin Orthop Relat Res  1998; (355S): S148-53.
 [http://dx.doi.org/10.1097/00003086-199810001-00016] [PMID:  9917635]

[134]
Chen Y. Orthopedic applications of gene therapy. J Orthop Sci  2001; 6(2): 199-207.
 [http://dx.doi.org/10.1007/s007760100072] [PMID:  11484110]

[135]
Hicks MJ, Funato K, Wang L, et al. Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma. Cancer Gene Ther  2015; 22(1): 1-8.
 [http://dx.doi.org/10.1038/cgt.2014.58] [PMID:  25501993]

[136]
Eggermont A, Finn O. Advances in immuno-oncology. Ann Oncol  2012; 23(Suppl. 8): viii5.
 [http://dx.doi.org/10.1093/annonc/mds255] [PMID: 22918929]

[137]
Rini B. Future approaches in immunotherapy. Semin Oncol  2014; 41(1) (Suppl. 5): S30-40.
 [http://dx.doi.org/10.1053/j.seminoncol.2014.09.005] [PMID:  25438998]

[138]
Weber JS, Mulé JJ. Cancer immunotherapy meets biomaterials. Nat Biotechnol  2015; 33(1): 44-5.
 [http://dx.doi.org/10.1038/nbt.3119] [PMID:  25574635]

[139]
Stephan SB, Taber AM, Jileaeva I, Pegues EP, Sentman CL, Stephan MT. Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol  2015; 33(1): 97-101.
 [http://dx.doi.org/10.1038/nbt.3104] [PMID:  25503382]

[140]
Bencherif SA, Warren Sands R, Ali OA, et al. Injectable cryogel-based whole-cell cancer vaccines. Nat Commun  2015; 6(1): 7556.
 [http://dx.doi.org/10.1038/ncomms8556] [PMID:  26265369]

[141]
Tayalia P, Mazur E, Mooney DJ. Controlled architectural and chemotactic studies of 3D cell migration. Biomaterials  2011; 32(10): 2634-41.
 [http://dx.doi.org/10.1016/j.biomaterials.2010.12.019] [PMID:  21237507]

[142]
Kim J, Li WA, Choi Y, et al. Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy. Nat Biotechnol  2015; 33(1): 64-72.
 [http://dx.doi.org/10.1038/nbt.3071] [PMID:  25485616]

[143]
Hori Y, Stern PJ, Hynes RO, Irvine DJ. Engulfing tumors with synthetic extracellular matrices for cancer immunotherapy. Biomaterials  2009; 30(35): 6757-67.
 [http://dx.doi.org/10.1016/j.biomaterials.2009.08.037] [PMID:  19766305]

[144]
Hsu W, Lesniak MS, Tyler B, Brem H. Local delivery of interleukin-2 and adriamycin is synergistic in the treatment of experimental malignant glioma. J Neurooncol  2005; 74(2): 135-40.
 [http://dx.doi.org/10.1007/s11060-004-6597-8] [PMID:  16193383]

[145]
Rhines LD, Sampath P, DiMeco F, et al. Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma. Neurosurgery  2003; 52(4): 872-80.
 [http://dx.doi.org/10.1227/01.NEU.0000053211.39087.D1] [PMID:  12657184]
Rights & Permissions Print Cite
Article Metrics
43
2
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1574888X18666230110154333	Print ISSN 1574-888X
Publisher Name Bentham Science Publisher	Online ISSN 2212-3946
Current Stem Cell Research & Therapy

Biomaterial Based Stem Cells Therapy for Cancer

Abstract

Graphical Abstract

Related Journals

Related Books

Related Articles
